All articles tagged with #ionis
AstraZeneca and Ionis have announced positive Phase III results for eplontersen, a drug for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a fatal neurodegenerative disease. Patients taking eplontersen recorded a 0.28-point average increase from baseline compared to a 25.06-point average increase in the placebo group. The drug is expected to generate over $3 billion in sales.
BrainStorm Cell Therapeutics' ALS treatment, NurOwn, will be discussed in an FDA advisory committee meeting after receiving a refusal to file letter in November. Ionis and AstraZeneca's rare disease drug, eplontersen, has completed a positive Phase III trial. Codiak BioSciences has filed for Chapter 11 bankruptcy. ArriVent Biopharma has raised $155 million in a Series B round. Endpoints has added three new journalists to their newsroom. Kristen Hege, a cancer researcher, has put her career on hold to hike the Pacific Crest Trail. Another biotech startup has faced a Phase II pileup in Parkinson's disease.